2-(4-羟基苯基)-噻唑-4-甲醛 | 885278-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-羟基苯基)-噻唑-4-甲醛
• 英文名称: 2-(4-hydroxyphenyl)thiazole-4-carboxaldehyde
• 英文别名: 2-(4-Hydroxyphenyl)thiazole-4-carbaldehyde；2-(4-hydroxyphenyl)-1,3-thiazole-4-carbaldehyde
• CAS: 885278-87-5
• 化学式: C₁₀H₇NO₂S
• 分子量: 205.237
• InChiKey: HAXXZLBEEWCVAX-UHFFFAOYSA-N

物化性质

• 沸点：
  422.5±51.0 °C(Predicted)
• 密度：
  1.391±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  罗丹宁 、 2-(4-羟基苯基)-噻唑-4-甲醛 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以70%的产率得到
  参考文献：
  名称：

  Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family

  摘要：

  The PIM family of serine/threonine kinases have become an attractive target for anti-cancer drug development, particularly for certain hematological malignancies. Here, we describe the discovery of a series of inhibitors of the PIM kinase family using a high throughput screening strategy. Through a combination of molecular modeling and optimization studies, the intrinsic potencies and molecular properties of this series of compounds was significantly improved. An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over other kinases. Two PIM-expressing leukemic cancer cell lines, MV4-11 and 1(562, were employed to evaluate the in vitro anti-proliferative effects of selected inhibitors. Encouraging activities were observed for many examples, with the best example (44) giving an IC55 of 0.75 mu M against the K562 cell line. These data provide a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.02.056
• 作为产物：
  描述：

  2-溴-4-醛基噻唑 、 4-羟基苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 为溶剂， 反应 24.0h， 以68%的产率得到2-(4-羟基苯基)-噻唑-4-甲醛
  参考文献：
  名称：

  Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family

  摘要：

  The PIM family of serine/threonine kinases have become an attractive target for anti-cancer drug development, particularly for certain hematological malignancies. Here, we describe the discovery of a series of inhibitors of the PIM kinase family using a high throughput screening strategy. Through a combination of molecular modeling and optimization studies, the intrinsic potencies and molecular properties of this series of compounds was significantly improved. An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over other kinases. Two PIM-expressing leukemic cancer cell lines, MV4-11 and 1(562, were employed to evaluate the in vitro anti-proliferative effects of selected inhibitors. Encouraging activities were observed for many examples, with the best example (44) giving an IC55 of 0.75 mu M against the K562 cell line. These data provide a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.02.056

文献信息

• [EN] SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS<br/>[FR] PYRAZOLES SUBSTITUÉS AGONISTES DU RÉCEPTEUR FFA4/GPR120
  申请人：AXXAM SPA

  公开号：WO2019175152A1

  公开（公告）日：2019-09-19

  The present invention refers to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). These compounds have FFA4/GPR120 receptor (FFA4) agonistic properties. The invention refers also to pharmaceutical compositions comprising these compounds, chemical processes for preparing them and their use in the treatment or prophylaxis of diseases associated with FFA4 receptor activity in animals, in particular humans.

  本发明涉及式(I)的化合物或其药学上可接受的盐：式(I)。这些化合物具有FFA4/GPR120受体（FFA4）激动性特性。该发明还涉及包含这些化合物的药物组合物，用于制备它们的化学过程以及它们在治疗或预防与动物（特别是人类）FFA4受体活性相关的疾病中的用途。
• SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS
  申请人：AXXAM S.p.A.

  公开号：EP3765446A1

  公开（公告）日：2021-01-20